Clover Health Investments: 2Q26 Earnings Call Transcript
Clover Health (2Q26 earnings call transcript) said first-half 2026 results included 48% MA membership growth, GAAP net income up $67 million YoY, and total revenue up more than $550 million YoY to $1.5 billion, with gross profit up $104 million. CEO cited Medicare Advantage Star rating recalculation to 4.5 stars for Payment Year 2027 after a court order, with CMS intending to appeal.
How this was made
The 30-second read
Why it matters
The key tradable update is the regulatory/payment-year star-rating recalculation to 4.5 stars for PY2027, which management frames as enabling reinvestment and supporting profitability through cohort maturation. However, CMS’s intent to appeal keeps legal uncertainty in play.
Market read
Traders may reprice Clover’s perceived 2027 reimbursement economics based on the confirmed 4.5-star enrollment outcome, while monitoring appeal-driven downside risk.
What to watch
Cohort maturation is emphasized, but the transcript does not provide new quantitative cohort tables or updated financial guidance for 2027, leaving traders to rely on prior assumptions.
Background
Clover is discussing 2Q26 results and linking business momentum to Medicare Advantage Star rating recalculation and maturation of member cohorts under its Clover Assistant AI care model.
Ticker impact
Clover says CMS recalculated Star ratings so all Medicare Advantage members are enrolled in 4.5-star plans for Payment Year 2027, with CMS intending to appeal.
Near-term sentiment may improve on the 4.5-star confirmation, but upside could be capped by the stated CMS appeal and ongoing uncertainty around future payment-year economics.
The transcript provides a concrete regulatory/payment-year update (4.5 stars for PY2027) and explicitly notes CMS’s intent to appeal, which can affect perceived durability of the economics.
Market effects
Highlights how Medicare Advantage star-rating mechanics can materially change insurer reinvestment capacity and perceived earnings durability for AI-enabled care models.
Management emphasizes growth engine in core New Jersey and Georgia markets, implying localized competitive intensity and enrollment focus.
Limited direct global relevance; primarily US Medicare Advantage reimbursement and regulatory-lifecycle risk.
Counterpoint
The 4.5-star benefit may be less durable if CMS’s appeal reverses or delays the economics, making the “flexibility” narrative contingent.
Key entities
- companyClover Health Investments
Subject of the earnings call transcript; management ties 2027 confidence to 4.5-star enrollment and AI-driven cohort maturation.
- regulatorCMS
U.S. Centers for Medicare and Medicaid Services recalculated Star ratings and filed notice of intent to appeal the district court decision.
- courtDistrict Court
Issued the ruling that led to the Star rating recalculation for Payment Year 2027.
- companyCounterpart Health
Mentioned as extending Clover Assistant’s clinically focused model across the healthcare market.
